November 5, 2026 | Developments since November 2
Organigram signed an agreement to acquire Aurora, introducing a board-supported transaction into Curaleaf’s takeover campaign. Massachusetts voters rejected an initiative that would have ended adult-use retail sales. Meanwhile, Tilray announced a transfer of cultivation and pre-roll production, Curaleaf reported higher revenue with narrower margins, and a federal appeals court revived a challenge to California’s cannabis labor requirements.
1. Organigram signs C$561 million Aurora acquisition agreement
Organigram and Aurora announced November 3 an acquisition agreement valuing Aurora’s fully diluted equity at approximately C$561 million. Both boards support the transaction.
The announced consideration is C$7.80 per Aurora share, with cash, stock and mixed elections subject to proration. The mixed option consists of C$3.75 cash plus 3.0431 Organigram shares. Consequently, the announced valuation should not be read as an unrestricted cash offer to every shareholder.
BAT will provide £100 million, approximately C$187.5 million at the announcement’s exchange rate, through a concurrent private placement. The companies expect shareholder meetings in December and completion in January 2027, subject to shareholder, regulatory and court approvals. businesswire.com businesswire.com
This materially advances the Aurora story covered in October: Aurora now has a signed alternative to Curaleaf’s hostile bid. Curaleaf’s November 3 earnings disclosure says it is evaluating the transaction and its options for continuing to pursue Aurora.
The proposed combination joins Organigram’s Canadian recreational business and European commercial operations with Aurora’s medical production and distribution network. The companies identify more than C$50 million in synergies; these remain projections rather than demonstrated integration savings. sec.gov
Sources: Joint acquisition announcement; Curaleaf’s response within its earnings disclosure.
2. Massachusetts voters reject repeal of adult-use cannabis sales
Massachusetts voters rejected Question 8 in the November 3 election, according to November 4 reporting from WBUR. The measure would have repealed the laws authorizing, regulating and taxing adult-use retail marijuana sales, effective January 1, 2028. WBUR News
The proposal’s transition provisions explain the magnitude of the vote for operators. Existing adult-use businesses would have been allowed to seek expedited medical dispensary licensing and sell remaining adult-use inventory to medical dispensaries. The Cannabis Control Commission would have retained authority over the medical market.
Its defeat preserves the existing adult-use framework. It removes this proposed statutory end date from cultivation, manufacturing and retail planning without changing underlying market prices, demand or business profitability.
The state’s official fiscal analysis estimated that adult-use cannabis taxes generated approximately $280 million in state revenue and $50 million in local revenue in fiscal 2025. Those figures describe the tax base implicated by the initiative, rather than new revenue created by its defeat. Ballot Question 8
Sources: WBUR election reporting; official ballot summary and fiscal analysis.
3. Tilray plans to move Foss cultivation to Masson and pre-roll production to Cayuga
Tilray announced November 2 that it will transfer cultivation from its Foss facility in Fenwick, Ontario, to Masson, Quebec, and pre-roll production to Cayuga, Ontario. Foss operations are expected to conclude by January 31, 2027, after a phased transition through current cultivation and harvest cycles.
Management says better-than-expected yields and optimization allow Masson’s annual cultivation capacity to increase from approximately 32.5 to 50 metric tonnes. That is a capacity statement, not evidence that the site has already produced 50 tonnes in a year.
The company targets approximately US$10 million in annualized savings, with the full run rate expected in fiscal 2028. Pre-rolls represent roughly one-third of its Canadian adult-use sales and grew 28% in fiscal 2026, according to Tilray.
This is a specific production-allocation decision: cultivation and manufacturing move to existing facilities while another site winds down. Whether it delivers the projected economics depends on transfer execution, realized output and costs. Masson’s anticipated restoration of EU-GMP certification in calendar 2027 is also a future milestone, not an approval already obtained. ir.tilray.com
Source: Tilray’s operating announcement.
4. Curaleaf revenue grows 10.9%, while gross margin declines
Curaleaf reported November 3 that third-quarter revenue reached US$352.7 million, up 10.9% year over year and 3.6% sequentially. Management reported domestic revenue growth of 8% and international growth of 28%; international revenue was approximately $59 million.
The margin figures qualify the growth story. GAAP gross margin was 48.3%, down 220 basis points year over year. Adjusted EBITDA was $77.6 million, representing a 22% margin, while the net loss attributable to Curaleaf from continuing operations was $37.4 million.
Quarter-end cash was $104.9 million. Management reported approximately $22 million of quarterly cash flow from continuing operations and maintained an approximately $150 million full-year operating cash-flow target. Its expectation that timing differences reverse next quarter remains forward-looking.
The results establish growth across both geographic segments, alongside lower gross and adjusted EBITDA margins. They do not establish a corresponding improvement in cultivation cost per gram or labor productivity. The next useful comparison is whether additional revenue converts into stronger margins and cash generation. sec.gov
Source: Curaleaf’s SEC-filed earnings release.
5. Ninth Circuit revives California cannabis retailer’s labor-peace challenge
On November 2, the Ninth Circuit vacated dismissal of Ctrl Alt Destroy v. Elliott and returned the case to the district court.
The retailer challenges California’s requirement that certain cannabis licensees enter, or agree to enter, labor peace agreements. The district court had dismissed the case under the “unclean hands” doctrine because the retailer’s business involved federally prohibited activity.
The appeals court concluded that the district court failed to perform the required balancing analysis. It instructed the lower court to consider the competing conduct and rights, including the retailer’s argument that California facilitates, regulates and profits from the activity it invokes against the business.
The decision does not invalidate California’s labor-peace requirement or resolve the retailer’s constitutional and federal-preemption arguments. It restores consideration of the case. The memorandum is also designated nonprecedential, subject to the Ninth Circuit’s rules.
Following Monday’s coverage of New York’s legislative repeal, this is a separate development through litigation. The two states’ requirements should not be treated as having changed together. law.justia.com
Source: November 2 court memorandum.
6. German flower listings expand as unweighted advertised prices fall
A November 3 analysis by Business of Cannabis reports that German medical cannabis flower listings increased from 1,378 SKUs in September 2025 to 2,381 in September 2026, approximately 73%.
Over the same period, the reported unweighted average price fell from €7.70 to €6.00 per gram, approximately 22%. The analysis attributes its product and pricing data to Flowzz, MedCanOneStop and online pharmacies.
The measurement matters. An unweighted listing average gives each observation equal influence, regardless of how much product patients actually purchase. It is neither a sales-weighted transaction price nor a wholesale export price. Changes in the product assortment can also change the average.
The findings document wider listed choice and lower average advertised pricing. They do not, by themselves, quantify unsold inventory or establish market-wide oversupply. For exporters and brands, the unresolved commercial questions are realized purchase prices, reorder volumes and whether particular genetics retain a premium within the broader assortment. The underlying transaction-level data were not available in the published analysis. businessofcannabis.com
Source: Business of Cannabis pricing analysis.
New licenses and market openings
Minnesota’s November 2 table lists 303 issued microbusiness licenses, up from 299 in the October 26 table covered Monday. Issued cultivator licenses remain at 24 and standalone retailer licenses at 20. The microbusiness increase represents additional licenses, not necessarily four newly opened stores or producing cultivation sites. Minnesota OCM application and license data. mn.gov
No new Kentucky, Texas or Virginia state licensing window or opening was verified for this edition. Election coverage has not been treated as authorization to operate in a new market.
What to watch next
November 5: TerrAscend reports after market close, with its earnings call scheduled for 5 p.m. Eastern. Company schedule. ir.terrascend.com
Aurora transaction: Curaleaf’s next formal response and the joint shareholder circular, including final financing, approval and consideration details.
Tilray production transfer: Completion of remaining Foss harvests, transfer costs and subsequent disclosure of realized Masson output.
California labor litigation: The district court’s balancing analysis and any subsequent decision on the underlying claims.
Minnesota, November 16: The existing event-organizer application closes at 4 p.m. Central ahead of the January 2027 licensing changes. OCM guidance. mn.gov
